Aclidinium bromide clinical trials

Studies by the year they started

29 studies that test it; most in 2009 (6)

Who runs them

Industry 26 · Other 3

AstraZeneca (25) · University of Dundee (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Milan (1) · Daewoong Pharmaceutical Co. LTD. (1)

Often tested with

Tested in the same studies.

Formoterol (10) · Budesonide (1) · Tiotropium (1)

Studies

Open first, then newest update. How each study uses aclidinium bromide is read from its arms, and is right about nine times in ten.

Testing it · 29

• Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsCompletedPhase 3AstraZenecaNCT03022097Written as Aclidinium bromide/formoterol Fixed-Dose Combination
• A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese ParticipantsCompletedPhase 1AstraZenecaNCT03276052Written as Aclidinium Bromide 400 μg
• Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC TrialCompletedPhase 4University of DundeeNCT02972476Written as Budesonide & formoterol fumarate and Aclidinium bromide
• The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in SmokersCompletedPhase 3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT03104634Written as Aclidinium bromide/formoterol fumarate dihydrate
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.CompletedPhase 4AstraZenecaNCT01966107Written as Aclidinium Bromide
• AMPLIFY - D6571C00001 Duaklir USA Phase III StudyCompletedPhase 3AstraZenecaNCT02796677Written as Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
• Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 3AstraZenecaNCT01437540Written as Aclidinium Bromide/Formoterol Fumarate
• Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT01572792Written as Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
• BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGHCompletedPhase 4AstraZenecaNCT02375724Written as Aclidinium Bromide
• Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)CompletedPhase 3AstraZenecaNCT01044459Written as Aclidinium Bromide 200 µg
• Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT01437397Written as Aclidinium Bromide/Formoterol Fumarate
• Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationCompletedPhase 3AstraZenecaNCT01462942Written as Aclidinium Bromide/Formoterol Fumarate
• Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)CompletedPhase 3AstraZenecaNCT01045161Written as Aclidinium bromide
• Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedPhase 2AstraZenecaNCT01120093Written as Aclidinium bromide 100 μg bid
• Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)CompletedPhase 3AstraZenecaNCT00891462Written as Aclidinium bromide
• Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)CompletedPhase 3AstraZenecaNCT00970268Written as Aclidinium bromide
• A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT00363896Written as Aclidinium bromide
• A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT00500318Written as Aclidinium Bromide
• Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2AstraZenecaNCT00868231Written as Aclidinium bromide 400 μg bid
• Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 3AstraZenecaNCT01001494Written as Aclidinium bromide 200 μg bid

See all 29 studies that test aclidinium bromide →

Codes

What other systems call aclidinium bromide · ClinicalTrials.gg INT005477

• MeSH (NLM) C542859aclidinium bromideOne source NLM
• UNII (FDA) UQW7UF9N91ACLIDINIUM BROMIDEConfirmed FDA, NLM, Wikidata
• RxNorm 1303097Confirmed FDA, Wikidata
• Wikidata Q27888207aclidinium bromideConfirmed FDA, NLM, Wikidata
• NCI Thesaurus C75999Aclidinium BromideOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.